These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 1560385)
21. Pharmacokinetic-pharmacodynamic modeling of the anticonvulsant and electroencephalogram effects of phenytoin in rats. Della Paschoa OE; Mandema JW; Voskuyl RA; Danhof M J Pharmacol Exp Ther; 1998 Feb; 284(2):460-6. PubMed ID: 9454785 [TBL] [Abstract][Full Text] [Related]
22. Simultaneous modeling of the pharmacokinetics and pharmacodynamics of midazolam and diazepam. Mould DR; DeFeo TM; Reele S; Milla G; Limjuco R; Crews T; Choma N; Patel IH Clin Pharmacol Ther; 1995 Jul; 58(1):35-43. PubMed ID: 7628181 [TBL] [Abstract][Full Text] [Related]
23. Pharmacodynamic modeling of the electroencephalographic effects of flumazenil in healthy volunteers sedated with midazolam. Fiset P; Lemmens HL; Egan TD; Shafer SL; Stanski DR Clin Pharmacol Ther; 1995 Nov; 58(5):567-82. PubMed ID: 7586951 [TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic-pharmacodynamic modelling of the interaction between flumazenil and midazolam in volunteers by aperiodic EEG analysis. Breimer LT; Burm AG; Danhof M; Hennis PJ; Vletter AA; de Voogt JW; Spierdijk J; Bovill JG Clin Pharmacokinet; 1991 Jun; 20(6):497-508. PubMed ID: 2044333 [TBL] [Abstract][Full Text] [Related]
25. Early clinical pharmacological trials with a novel partial benzodiazepine agonist/antagonist Ro 17-1812 using pharmaco-EEG and psychometry. Saletu B; Grünberger J; Linzmayer L Methods Find Exp Clin Pharmacol; 1986 Jun; 8(6):373-89. PubMed ID: 3736281 [TBL] [Abstract][Full Text] [Related]
26. Quantification of the EEG effect of midazolam by aperiodic analysis in volunteers. Pharmacokinetic/pharmacodynamic modelling. Breimer LT; Hennis PJ; Burm AG; Danhof M; Bovill JG; Spierdijk J; Vletter AA Clin Pharmacokinet; 1990 Mar; 18(3):245-53. PubMed ID: 2323155 [TBL] [Abstract][Full Text] [Related]
27. Physostigmine reversal of midazolam-induced electroencephalographic changes in healthy subjects. Ebert U; Oertel R; Kirch W Clin Pharmacol Ther; 2000 May; 67(5):538-48. PubMed ID: 10824633 [TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of heptabarbital using aperiodic EEG analysis. Mandema JW; Danhof M J Pharmacokinet Biopharm; 1990 Oct; 18(5):459-81. PubMed ID: 1979991 [TBL] [Abstract][Full Text] [Related]
29. On the central effects of a new partial benzodiazepine agonist Ro 16-6028 in man: pharmaco-EEG and psychometric studies. Saletu B; Grünberger J; Linzmayer L Int J Clin Pharmacol Ther Toxicol; 1989 Feb; 27(2):51-65. PubMed ID: 2921096 [TBL] [Abstract][Full Text] [Related]
30. Pharmacodynamic analysis of the interaction between tiagabine and midazolam with an allosteric model that incorporates signal transduction. Jonker DM; Vermeij DA; Edelbroek PM; Voskuyl RA; Piotrovsky VK; Danhof M Epilepsia; 2003 Mar; 44(3):329-38. PubMed ID: 12614388 [TBL] [Abstract][Full Text] [Related]
31. Selectivity of action of 8-alkylamino analogues of N6-cyclopentyladenosine in vivo: haemodynamic versus anti-lipolytic responses in rats. van Schaick EA; Tukker HE; Roelen HC; IJzerman AP; Danhof M Br J Pharmacol; 1998 Jun; 124(3):607-18. PubMed ID: 9647488 [TBL] [Abstract][Full Text] [Related]
32. Drug discrimination analysis of midazolam under a three-lever procedure. II: Differential effects of benzodiazepine receptor agonists. Sannerud CA; Ator NA J Pharmacol Exp Ther; 1995 Oct; 275(1):183-93. PubMed ID: 7562548 [TBL] [Abstract][Full Text] [Related]
33. Mixed-effects modeling of the influence of midazolam on propofol pharmacokinetics. Vuyk J; Lichtenbelt BJ; Olofsen E; van Kleef JW; Dahan A Anesth Analg; 2009 May; 108(5):1522-30. PubMed ID: 19372331 [TBL] [Abstract][Full Text] [Related]
34. A comparison of spectral edge, delta power, and bispectral index as EEG measures of alfentanil, propofol, and midazolam drug effect. Billard V; Gambus PL; Chamoun N; Stanski DR; Shafer SL Clin Pharmacol Ther; 1997 Jan; 61(1):45-58. PubMed ID: 9024173 [TBL] [Abstract][Full Text] [Related]
35. Effects of a specific benzodiazepine antagonist (RO 15-1788) on cerebral blood flow. Forster A; Juge O; Louis M; Nahory A Anesth Analg; 1987 Apr; 66(4):309-13. PubMed ID: 3105357 [TBL] [Abstract][Full Text] [Related]
36. Rate of change of blood concentrations is a major determinant of the pharmacodynamics of midazolam in rats. Cleton A; Mazee D; Voskuyl RA; Danhof M Br J Pharmacol; 1999 May; 127(1):227-35. PubMed ID: 10369477 [TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats. Cox EH; Van Hemert JG; Tukker EJ; Danhof M J Pharmacol Toxicol Methods; 1997 Oct; 38(2):99-108. PubMed ID: 9403781 [TBL] [Abstract][Full Text] [Related]
38. Pharmacodynamic interaction between midazolam and a low dose of ethanol in vivo. Hoyo-Vadillo C; Mandema JW; Danhof M Life Sci; 1995; 57(4):325-33. PubMed ID: 7603305 [TBL] [Abstract][Full Text] [Related]
39. Modelling acute tolerance to the EEG effect of two benzodiazepines. Ihmsen H; Albrecht S; Hering W; Schüttler J; Schwilden H Br J Clin Pharmacol; 2004 Feb; 57(2):153-61. PubMed ID: 14748814 [TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic/pharmacodynamic relationship of benzodiazepines in the direct cortical stimulation model of anticonvulsant effect. Hoogerkamp A; Arends RH; Bomers AM; Mandema JW; Voskuyl RA; Danhof M J Pharmacol Exp Ther; 1996 Nov; 279(2):803-12. PubMed ID: 8930187 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]